Zhejiang Conba Pharmaceutical's controlling shareholder reduces stake

Zhejiang Conba Pharmaceutical announced its controlling shareholder, Conba Group Co., Ltd., and its concerted party, Hu Jiqiang, have reduced their combined stake from 13.944% to 12.992%, a decrease of 0.952%. This reduction occurred between September 4, 2025, and November 6, 2025, through centralized bidding on the Shanghai Stock Exchange, with average prices of CNY4.58/share and CNY4.63/share respectively.

The company also announced the cancellation of 2,029,200 stock options from its 2022 stock option incentive plan due to employee retirement, resignation, and performance evaluations. Separately, the company declared the second exercise period for the initial grant of 15,901,800 stock options and the first exercise period for the reserved grant of 2,914,000 stock options have met their vesting conditions.

To comply with the latest legal and regulatory requirements, Zhejiang Conba Pharmaceutical will amend its articles of association, shareholder meeting rules, board of directors meeting rules, and related party transaction system. These amendments will eliminate the supervisory board, transfer its responsibilities to the audit committee, and update the company's total share capital to 2,506,458,271 shares, reflecting the cancellation of repurchased shares.